Skip to main content
SpringerLink
Log in

Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

We studied the serum phosphorus (P) level of 110 patients with multiple myeloma (MM) (age range 42–83 years, median 62 years) and evaluated the relationship between that and other prognostic factors. Serum P level significantly correlated with the prognostic factors that are relevant to renal dysfunction: serum creatinine (P<0.00000001), serum β2-microglobulin (P=0.00000088), serum uric acid (P=0.0000014), and corrected serum calcium (cCa P=0.000067). Although it also correlated with the percentage of plasma cells in bone marrow nucleated cells (BMPC%) and the hemoglobin (Hb) and leukocyte counts, the significance was less than for the other four prognostic factors. Serum creatinine, BMPC%, leukocyte count, serum uric acid, bone lesions, β2-microglobulin, and serum cCa were all significantly higher and Hb significantly was lower in the MM patients with hyperphosphatemia (serum P>3.8 mg/dl). The survival time was significantly shorter in these patients (P=0.000087). Multivariate analysis (Cox’s proportional hazards regression model) showed that the serum P level is a significant negative prognostic factor in MM patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Holick MF, Krane SM, Potts JT (1987) Phosphorus, disorders of bone and mineral metabolism. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS (eds) Harrison’s principles of internal medicine, 11th edn. McGraw-Hill, New York, pp 1859–1860

    Google Scholar 

  2. Pettersson T, Hortling L, Teppo AM, Toetterman KJ, Fyhrquist F (1987) Phosphate binding by a myeloma protein. Acta Med Scand 222:89–91

    PubMed  CAS  Google Scholar 

  3. Mandry JM, Posner MR, Tucci JR, Eil C (1991) Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin. Cancer 68:1092–1094

    Article  PubMed  CAS  Google Scholar 

  4. Busse JC, Gelhard MA, Byrenes JJ, Hellman R, Vaamonde CA (1987) Pseudohyperphosphatemia and dysproteinemia. Arch Intern Med 147:2045–2046

    Article  PubMed  CAS  Google Scholar 

  5. Sonnenblick M, Eylath U, Brisk R, Eldad C, Hershko C (1986) Paraprotein interference with colorimetry of phosphate in serum of some patients with multiple myeloma. Clin Chem 32:1537–1539

    PubMed  CAS  Google Scholar 

  6. Adler SG, Laidlaw SA, Lubran MM, Kopple JD (1988) Hyperglobulinemia may spuriously elevate measured serum inorganic phosphate levels. Am J Kidney Dis 11:260–263

    PubMed  CAS  Google Scholar 

  7. Oren S, Feldman A, Turkot S, Lugassy G (1994) Hyperphosphatemia in multiple myeloma. Ann Hematol 69:41–43

    Article  PubMed  CAS  Google Scholar 

  8. Marcu CB, Hotchkiss M (2004) Pseudohyperphosphatemia in a patient with multiple myeloma. Conn Med 68:71–77

    PubMed  Google Scholar 

  9. Chronic Leukemia–Myeloma Taskforce, National Cancer Institute (1973) Proposed guidelines for protocol studies 11. Plasma cell myeloma. Cancer Chemother Rep 3 4:145–158

    Google Scholar 

  10. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36:842–854

    Article  PubMed  CAS  Google Scholar 

  11. Alexanian R, Salmon S, Bonnet J, Gehan E, Haut A, Weick J (1977) Combination therapy for multiple myeloma. Cancer 40:2765–2771

    Article  PubMed  CAS  Google Scholar 

  12. Peto, R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient II: analysis and examples. Br J Cancer 35:l–39

    Google Scholar 

  13. Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal proteins. BMJ 4:643–646

    Article  PubMed  CAS  Google Scholar 

  14. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  15. Cox DR (1972) Regression models and life tables. J R Stat Soc 34:187–196

    Google Scholar 

  16. Weinberg J, Adler AJ (1989) Spurious hyperphosphatemia in patients with dysglobulinemia. Miner Electrolyte Metab 15:185–186

    PubMed  CAS  Google Scholar 

  17. McCloskey EV, Galloway J, Morgan MA, Kanis JA (1989) Pseudohyperphosphatemia in multiple myeloma. BMJ 299:1381–1382

    PubMed  CAS  Google Scholar 

  18. Barutcuoglu B, Parildar Z, Mutaf I, Habif S, Bayindir O (2003) Spuriously elevated inorganic phosphate level in a multiple myeloma patient. Clin Lab Haematol 25:271–274

    Article  PubMed  CAS  Google Scholar 

  19. Loghman-Adham M, Walton D, Iverius PH, Deiss A, Knight JA, Cheung AK (1997) Spurious hypophosphatemia in a patient with multiple myeloma. Am J Kidney Dis 30:571–575

    Article  PubMed  CAS  Google Scholar 

  20. Caras JA (1997) Spurious hypophosphatemia associated with multiple myeloma. Endocr Pract 3:135–136

    PubMed  CAS  Google Scholar 

  21. Dash T, Parker MG, Lafayettw RA (1997) Profound hypophosphatemia and isolated hyperphosphaturia in two case of multiple myeloma. Am J Kidney Dis 29:445–448

    Article  PubMed  CAS  Google Scholar 

  22. Weisbord SD, Chaudhuri A, Blauth K, DeRubertis FR (2003) Monoclonal gammopathy and spurious hypophosphatemia. Am J Med Sci 325:98–100

    Article  PubMed  Google Scholar 

  23. Engle RL Jr, Wallis LA (1957) Multiple myeloma and the adult Fanconi syndrome. Am J Med 22:5–18

    Article  PubMed  Google Scholar 

  24. Smithline N, Kassirer JP, Cohen JJ (1976) Light-chain nephropathy: renal tubular dysfunction associated with light-chain proteinuria. N Engl J Med 294:71–74

    PubMed  CAS  Google Scholar 

  25. Alexanian R, Balgerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, Monto RW (1975) Prognostic factors in multiple myeloma. Cancer 36:1192–1201

    Article  PubMed  CAS  Google Scholar 

  26. Merlini G, Waldenström JG, Jayakar SD (1980) A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 55:1011–1019

    PubMed  CAS  Google Scholar 

  27. Medical Research Council (1973) Report on the first myelomatosis trial. Part 1. Analysis of presenting features of prognostic importance. Br J Haematol 24:123–139

    Article  Google Scholar 

  28. Bladé J, Rozman C, Cervantes F, Reverter J-C, Montserat E (1989) A new prognostic system for multiple myeloma based on easily available parameters. Br J Haematol 172:507–511

    Article  Google Scholar 

  29. San Miguel JF, Sànchez J, Gonzalez M (1989) Prognostic factors and classification in multiple myeloma. Br J Haematol 59:113–118

    CAS  Google Scholar 

  30. Cavo M, Galieni P, Zuffa E, Baccarani M, Gobbi M, Tura S (1989) Prognostic variables and clinical staging in multiple myeloma. Blood 74:1774–1780

    PubMed  CAS  Google Scholar 

  31. Murakami H, Kawada T, Saitoh T, Uchiumi H, Moridaira K, Matsushima T, Tsukamoto N, Tamura J, Morita K, Sawamura M, Karasawa M, Miyawaki S, Shinonome S, Shimano S, Sato S, Ogawara H, Tsuchiya J (1999) A staging system for multiple myeloma based on the morphology of myeloma cells. Eur J Haematol 62:63–67

    Article  PubMed  CAS  Google Scholar 

  32. Jacobson JL, Hussein MA, Barlogie B, Durie BGM, Crowley JJ (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 122:441–450

    Article  PubMed  Google Scholar 

  33. Durie BMG, Kyle RA, Belch A, Bensinger W, Bladé J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Poweles R, Singhal DS, Sirohi B, Sonnenveld P, Tricot G, Ness BV (2003) Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J 4:379–398

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1, Omori-nishi, Ota-Ku, Tokyo, 143-8541, Japan

    Masanori Umeda, Shinya Okuda, Haruka Izumi, Daisuke Nagase, Yoshinori Fujimoto, Yasuyuki Sugasawa, Chiaki Arai, Kazuhiko Natori, Masako Katoh & Yasunobu Kuraishi

Authors
  1. Masanori Umeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinya Okuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haruka Izumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daisuke Nagase
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshinori Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuyuki Sugasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chiaki Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuhiko Natori
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masako Katoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasunobu Kuraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masanori Umeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Umeda, M., Okuda, S., Izumi, H. et al. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma. Ann Hematol 85, 469–473 (2006). https://doi.org/10.1007/s00277-006-0095-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-006-0095-3

Keywords

Search

Navigation